Peter Altman Biography and Net Worth
Dr. Altman has served as our President and CEO since 2002. He was CEO (1999 to 2003) and board member (1999 to 2014) of CareDx (NASDAQ: CDNA), a developer of a gene-based diagnostics for cardiac and other organ transplantation. He was CEO for Lumen Therapeutics from 2004 to 2005, an early-stage pharmaceutical company. He has extensive experience in life science research and product development, is named inventor in 45 U.S. patents, and has authored 40 scientific publications. Dr. Altman currently serves as a director on the board of Oncocyclist Biotech. He received his Ph.D. in Bioengineering/Pharmaceutical Chemistry from the University of California, San Francisco and University of California, Berkeley, his Management of Technology certificate from the Walter A. Haas School of Business at the University of California, Berkeley, and both his Master of Science and Bachelor of Science in Mechanical Engineering from the Columbia University School of Engineering and Applied Sciences. Dr. Altman has been elected Fellow of the American Heart Association.
What is Peter Altman's net worth?
The estimated net worth of Peter Altman is at least $308.84 thousand as of April 29th, 2026. Dr. Altman owns 280,766 shares of BioCardia stock worth more than $308,843 as of May 6th. This net worth evaluation does not reflect any other assets that Dr. Altman may own. Learn More about Peter Altman's net worth.
How do I contact Peter Altman?
Has Peter Altman been buying or selling shares of BioCardia?
During the past quarter, Peter Altman has bought $6,780.00 of BioCardia stock. Most recently, on Wednesday, April 29th, Peter Altman bought 5,000 shares of BioCardia stock. The stock was acquired at an average cost of $1.11 per share, with a total value of $5,550.00. Following the completion of the transaction, the chief executive officer now directly owns 280,766 shares of the company's stock, valued at $311,650.26. Learn More on Peter Altman's trading history.
Are insiders buying or selling shares of BioCardia?
In the last twelve months, BioCardia insiders bought shares 24 times. They purchased a total of 926,593 shares worth more than $1,304,989.44. The most recent insider tranaction occured on April, 29th when CEO Peter Altman bought 5,000 shares worth more than $5,550.00. Insiders at BioCardia own 17.4% of the company.
Learn More about insider trades at BioCardia. Information on this page was last updated on 4/29/2026.
Peter Altman Insider Trading History at BioCardia
| Transaction Date | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/29/2026 | Buy | 5,000 | $1.11 | $5,550.00 | 280,766 |  |
| 4/21/2026 | Buy | 400 | $1.23 | $492.00 | 275,766 | |
| 4/20/2026 | Buy | 600 | $1.23 | $738.00 | 275,366 | |
| 2/4/2026 | Buy | 5,000 | $1.13 | $5,650.00 | 273,866 | |
| 1/21/2026 | Buy | 300 | $1.34 | $402.00 | 268,866 | |
| 1/20/2026 | Buy | 600 | $1.32 | $792.00 | 268,566 | |
| 12/17/2025 | Buy | 900 | $1.30 | $1,170.00 | 267,966 | |
| 12/16/2025 | Buy | 200 | $1.37 | $274.00 | 267,066 | |
| 9/19/2025 | Buy | 48,000 | $1.25 | $60,000.00 | 216,762 | |
| 8/22/2025 | Buy | 700 | $1.83 | $1,281.00 | 168,762 | |
| 8/13/2025 | Buy | 100 | $1.83 | $183.00 | 168,062 | |
| 8/12/2025 | Buy | 400 | $1.75 | $700.00 | 167,962 | |
| 8/11/2025 | Buy | 1,700 | $1.76 | $2,992.00 | 167,562 | |
| 6/30/2025 | Buy | 24,096 | $2.08 | $50,119.68 | 165,862 | |
| 5/30/2025 | Buy | 100 | $2.21 | $221.00 | 141,766 | |
| 5/22/2025 | Buy | 700 | $1.89 | $1,323.00 | 141,666 | |
| 5/20/2025 | Buy | 1,600 | $2.08 | $3,328.00 | 140,966 | |
| 5/16/2025 | Buy | 300 | $2.43 | $729.00 | 139,366 | |
| 5/14/2025 | Buy | 100 | $2.99 | $299.00 | 139,066 | |
| 4/23/2025 | Buy | 26,246 | $1.91 | $50,129.86 | 138,966 | |
| 4/15/2025 | Buy | 100 | $2.14 | $214.00 | 112,720 | |
| 4/10/2025 | Buy | 300 | $1.99 | $597.00 | 112,320 | |
| 4/7/2025 | Buy | 500 | $1.96 | $980.00 | 112,020 | |
| 4/3/2025 | Buy | 1,200 | $2.24 | $2,688.00 | 109,620 | |
| 3/3/2025 | Buy | 500 | $2.11 | $1,055.00 | 108,420 | |
| 2/7/2025 | Buy | 600 | $2.48 | $1,488.00 | 107,920 | |
| 1/29/2025 | Buy | 500 | $2.40 | $1,200.00 | 107,081 | |
| 12/23/2024 | Buy | 1,000 | $2.06 | $2,060.00 | 106,581 | |
| 12/5/2024 | Buy | 250 | $2.22 | $555.00 | 105,581 | |
| 11/15/2024 | Buy | 1,350 | $1.87 | $2,524.50 | 105,331 | |
| 7/1/2024 | Buy | 300 | $3.05 | $915.00 | 39,745 | |
| 6/28/2024 | Buy | 200 | $2.99 | $598.00 | 39,445 | |
| 6/21/2024 | Buy | 500 | $3.29 | $1,645.00 | 39,245 | |
| 6/14/2024 | Buy | 500 | $3.52 | $1,760.00 | 38,745 | |
| 6/10/2024 | Buy | 1,000 | $3.36 | $3,360.00 | 38,245 | |
| 4/19/2024 | Buy | 183 | $5.55 | $1,015.65 | 37,246 | |
| 3/28/2024 | Buy | 33 | $5.85 | $193.05 | 37,063 | |
| 2/13/2024 | Buy | 7,207 | $6.90 | $49,728.30 | 37,029 | |
| 5/26/2023 | Buy | 413 | $24.00 | $9,912.00 | 31,282 | |
| 1/11/2023 | Buy | 6 | $28.05 | $168.30 | 23,581 | |
| 9/23/2022 | Buy | 93 | $28.05 | $2,608.65 | 21,896 | |
| 9/21/2022 | Buy | 183 | $28.80 | $5,270.40 | 21,596 | |
| 6/10/2022 | Buy | 300 | $21.90 | $6,570.00 | 21,413 | |
| 5/13/2022 | Buy | 179 | $20.70 | $3,705.30 | 23,209 | |
| 5/11/2022 | Buy | 66 | $19.50 | $1,287.00 | 22,276 | |
| 4/28/2022 | Buy | 153 | $23.85 | $3,649.05 | 22,029 | |
| 4/18/2022 | Buy | 900 | $20.85 | $18,765.00 | 21,876 | |
| 11/18/2021 | Buy | 333 | $33.00 | $10,989.00 | | |
| 8/17/2021 | Buy | 233 | $44.10 | $10,275.30 | 15,527 | |
| 12/1/2020 | Buy | 66 | $37.35 | $2,465.10 | 13,546 | |
| 11/27/2020 | Buy | 213 | $35.55 | $7,572.15 | 13,546 | |
| 11/12/2020 | Buy | 133 | $31.05 | $4,129.65 | 13,726 | |
| 11/10/2020 | Buy | 166 | $29.70 | $4,930.20 | 13,593 | |
| 3/24/2020 | Buy | 80 | $43.50 | $3,480.00 | 11,460 | |
| 3/19/2020 | Buy | 26 | $44.25 | $1,150.50 | 11,380 | |
| 3/12/2020 | Buy | 226 | $47.25 | $10,678.50 | 11,120 | |
| 6/5/2019 | Buy | 133 | $15.30 | $2,034.90 | | |
| 5/28/2019 | Buy | 13 | $19.20 | $249.60 | | |
| 5/17/2019 | Buy | 140 | $17.25 | $2,415.00 | | |
| 5/1/2019 | Buy | 733 | $16.20 | $11,874.60 | | |
| 2/13/2019 | Buy | 3 | $23.85 | $71.55 | | |
| 11/16/2018 | Buy | 426 | $35.10 | $14,952.60 | | |
| 11/13/2018 | Buy | 260 | $32.40 | $8,424.00 | | |
| 11/9/2018 | Buy | 33 | $37.50 | $1,237.50 | | |
| 11/2/2018 | Buy | 26 | $37.80 | $982.80 | | |
| 10/30/2018 | Buy | 20 | $38.25 | $765.00 | | |
| 10/26/2018 | Buy | 256 | $35.40 | $9,062.40 | | |
| 9/20/2018 | Buy | 73 | $26.10 | $1,905.30 | | |
| 9/18/2018 | Buy | 46 | $23.85 | $1,097.10 | | |
| 9/12/2018 | Buy | 106 | $20.55 | $2,178.30 | | |
| 9/5/2018 | Buy | 333 | $19.95 | $6,643.35 | | |
| 8/27/2018 | Buy | 100 | $21.90 | $2,190.00 | | |
| 6/11/2018 | Buy | 200 | $21.75 | $4,350.00 | | |
| 4/18/2018 | Buy | 66 | $21.75 | $1,435.50 | | |
| 3/20/2018 | Buy | 333 | $30.45 | $10,139.85 | | |
BioCardia Company Overview
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Read More
Volume
2,776 shs
Average Volume
65,829 shs
Market Capitalization
$12.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.56
